Health Economics›Breast cancer›Adjuvant chemotherapy

Adjuvant chemotherapy

Breast cancer · 30 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	TNBC	R 286 955	14d	~5.8 mo	~15.5 mo	~2	~R 573 911 PFS proxy · indirect	40
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~4.3 mo	~23.7 mo	~2	~R 38 164 PFS proxy · indirect	1
MMM Variant #01	—	R 4 862	21d	—	—	~6	~R 29 173 indirect	—
Epirubicin monotherapy Variant #01	—	R 3 200	21d	—	—	7	R 22 400 PFS proxy	1
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~8.0 mo	~11.5 mo	~4	~R 11 686 PFS proxy · indirect	11
TAC (Docetaxel) Variant #01	—	R 2 905	21d	—	—	6	R 17 428 PFS proxy	2
Epirubicin and Paclitaxel (EP) Variant #01	—	R 2 715	21d	~10.8 mo	~22.4 mo	~6	~R 16 290 PFS proxy · indirect	2
Cyclophosphamide and Epirubicin (EC) Variant #01	—	R 2 429	21d	~8.0 mo	~20.3 mo	~8	~R 19 434 PFS proxy · indirect	1
Cyclophosphamide and Docetaxel (TC) Variant #01	—	R 2 423	21d	—	—	~4	~R 9 690 indirect	—
FEC Variant #01	—	R 2 049	21d	—	—	2	R 4 097 PFS proxy	7
Doxorubicin and Paclitaxel (AT) Variant #01	—	R 1 609	21d	—	~25.3 mo	~9	~R 13 972 PFS proxy · indirect	1
FAC Variant #11	TNBC	R 1 076	21d	—	—	9	R 9 685 PFS proxy	1
FAC Variant #11	—	R 1 076	21d	—	—	9	R 9 685 PFS proxy	1
Capecitabine monotherapy Variant #01	TNBC	R 1 039	21d	—	—	8	R 8 309 PFS proxy	2
Capecitabine monotherapy Variant #01	—	R 1 039	21d	—	—	8	R 8 309 PFS proxy	2
Carboplatin and Paclitaxel (CP) Variant #02	TNBC	R 1 025	21d	~12.6 mo	~28.2 mo	~9	~R 9 222 PFS proxy · indirect	2
CMFT Variant #01	—	R 910	28d	—	—	~2	~R 1 819 indirect	—
Doxorubicin monotherapy Variant #01	—	R 902	21d	~6.8 mo	~13.8 mo	~9	~R 8 114 PFS proxy · indirect	3
Cyclophosphamide and Doxorubicin (AC) Variant #01	—	R 864	21d	—	—	6	R 5 185 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) Variant #01	TNBC	R 864	21d	—	—	6	R 5 185 PFS proxy	1
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) Variant #01	—	R 770	14d	—	—	6	R 4 621 PFS proxy	1
Paclitaxel monotherapy Variant #02	ERBB2	R 734	28d	~6.4 mo	~16.8 mo	~7	~R 5 141 PFS proxy · indirect	28
Paclitaxel monotherapy Variant #02	—	R 734	28d	~6.4 mo	~16.8 mo	~7	~R 5 141 PFS proxy · indirect	28
Vinorelbine monotherapy Variant #01	—	R 458	21d	~4.0 mo	~10.1 mo	~12	~R 5 490 PFS proxy · indirect	18
CMF Variant #01	—	R 291	28d	—	—	2	R 582 PFS proxy	4
CMF Variant #01	TNBC	R 291	28d	—	—	2	R 582 PFS proxy	4
Dose-dense Doxorubicin monotherapy Partial	—	—	—	—	—	—	—	—
Dose-dense Cyclophosphamide monotherapy Partial	—	—	—	—	—	—	—	—
Dose-dense Epirubicin monotherapy Partial	—	—	—	—	—	—	—	—
Bevacizumab-containing therapy Partial	TNBC	—	—	—	—	—	—	—

30 of 30 regimens shown